Ainos enrolls first subject for study of VELDONA-based animal drug

Ainos has enrolled the first subject for its Taiwanese clinical study of VELDONA-based animal drug in treating feline chronic gingivostomatitis, a serious and painful chronic cat oral disease characterized by inflammation or abnormal proliferation in the oral cavity. Dosing of the first subject is expected to occur on July 26, 2024. This animal clinical study is a randomized, double-blind, parallel, single-center, multiple-dose oral drug trial designed to evaluate the safety, tolerability, and efficacy of low-dose oral interferons in the treatment of FCGS. The clinical site in Taiwan is expected to enroll 30 subjects. This study builds on the animal health research of Ainos’ VELDONA, a low-dose oral interferon alpha formulation that was initially approved by the Texas Department of Health in 1985 for treating feline leukemia in cats and canine parvovirus in dogs. The trial aims to complete the enrollment of 30 subjects by the end of 2024 and to finalize the trial report in the first quarter of 2025. If the results meet expectations, Ainos will initiate the next phase involving an application to a clinical field trial for an animal drug certificate from the Animal and Plant Health Inspection Agency under Taiwan’s Ministry of Agriculture.